To further enhance the quality of Onco (ISSN: 2673-7523) and the papers published in it, under the guidance of our Editor-in-Chief, Dr. Constantin N. Baxevanis, the journal has updated and revised its aims and scope. The original scope and the updated version are listed below.
| Scope (new version): |
Scope (old version): |
- Cancer cell signaling;
- Cancer genetics and molecular targets;
- Cancer epigenetics and heterogeneity;
- Carcinogenesis and cancer evolution;
- Microbiome and cancer;
- Cancer metabolomics;
- Cancer biomarkers;
- Cancer dormancy;
- Novel targeted and immune cancer therapies;
- Randomized clinical trials;
- oncotargets;
- cancer therapies;
- clinical reports proposing novel therapeutic regimens.
|
- Cancer cell signaling;
- Cancer genetics and molecular targets;
- Cancer epigenetics and heterogeneity;
- Carcinogenesis and cancer evolution;
- Microbiome and cancer;
- Cancer metabolomics;
- Cancer biomarkers;
- Cancer dormancy;
- Novel targeted and immune cancer therapies;
- Randomized clinical trials.
|
For more detailed information, please visit the following link: https://www.mdpi.com/journal/onco/about.
Onco Editorial Office
